Using Hanlikang and BTK inhibitors to treat newly diagnosed mantle cell lymphoma

A Prospective Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma

This study tests if a new treatment combining Hanlikang and BTK inhibitors can help people who have just been diagnosed with mantle cell lymphoma feel better.

Quick facts

• Study type: Observational
• Enrollment: 100 (estimated)
• Ages: 18 Years to 90 Years
• Sex: All
• Sponsor: Zhengzhou University (Academic / other)
• Drugs / interventions: chemotherapy, immunotherapy
• Locations: 1 site (Zhengzhou, Henan)
• Trial ID: NCT05506410 on ClinicalTrials.gov

What this trial studies

This observational clinical study investigates the effectiveness of Hanlikang combined with BTK inhibitors in patients who have been newly diagnosed with mantle cell lymphoma. It is an open-label, single-arm, multicenter study that aims to assess the treatment outcomes in a prospective manner. Participants will receive Rituximab as part of their treatment regimen, and the study will monitor their response to the therapy over time.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18-70 with confirmed mantle cell lymphoma and specific health criteria.

Not a fit: Patients with severe comorbidities or those who do not meet the eligibility criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new effective treatment option for patients with newly diagnosed mantle cell lymphoma.

How similar studies have performed: While this approach is being explored, similar studies have shown promise in treating mantle cell lymphoma with targeted therapies.

Eligibility criteria

Inclusion Criteria:

1. Age 18-70, ECOG score 0-2;
2. Estimated survival time \>6 months;
3. Mantle cell lymphoma was confirmed by pathology.
4. Acceptable hematological indexes without chemotherapy contraindications; Neutrophil absolute value ≥1.0×10\^9 /L, PLT≥75×10\^9 /L, hemoglobin ≥80g/L (except patients with lymphoma bone marrow infiltration);
5. At least one measurable lesion. For intrnodal lesions, they were defined as long diameter ≥1.5cm and short diameter ≥1.0cm; For r extranodal lesions, the length should be ≥1.0cm;

7\. Liver function: TBIL≤1.5×ULN; ALT or AST ≤2.5 x ULN; Alkaline phosphatase ≤3×ULN in patients with non-bone invasion;

8\. Kidney function: serum creatinine ≤1.5×ULN;

9\. Excluding other major diseases, the heart function is normal;

10 Women and men of childbearing age and their spouses are willing to use adequate contraception throughout the study period, and women of childbearing age must have a negative serum pregnancy test within 7 days before the first dose;

11 Subjects voluntarily participated in the clinical trial, signed the informed consent form, and cooperated with the follow-up;

12\. There is no other relevant treatment including traditional Chinese medicine (anti-tumor), immunotherapy, biologic therapy (except anti-bone metastasis and other symptoms);

Exclusion Criteria:

1. Patients with definite neuropathy or psychosis, including dementia or seizures, a history of psychotropic substance abuse and inability to abstinence, or other substantial lesions that may increase CNS toxicity;
2. Participating in other clinical trials or participating in other clinical investigators 4 weeks before enrollment (except those not receiving treatment);
3. Systemic autoimmune disease or immune deficiency;
4. Refusing to collect blood samples;
5. Allergic to any drug in the protocol;
6. Pregnant and lactating women;
7. Major diseases that can cause test interference and uncontrolled active infected persons;
8. Primary or secondary central tumor;
9. Contraindications to chemotherapy;
10. Not considered suitable for inclusion.
11. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infections (other than nail bed skin fungal infections) or any major systemic infection event requiring intravenous antibiotic treatment or hospitalization (other than neoplastic fever) within 4 weeks prior to enrollment;

13\. Application of other antitumor therapies (such as radiotherapy, chemotherapy, hormone therapy, biotherapy, immunotherapy);

14\. Other serious medical conditions that may limit the subject's participation in the study, such as uncontrolled diabetes; Severe cardiac insufficiency (NYHA grade II or above); Acute coronary syndrome in the last 6 months; Coronary revascularization such as stenting, cabG, and other cardiac and macrovascular procedures within the last 6 months; Severe arrhythmias include frequent ventricular premature, ventricular tachycardia, rapid atrial fibrillation/flutter, and severe bradycardia. Uncontrolled hypertension: systolic blood pressure \>150mmHg, diastolic blood pressure \>100mmHg. Gastric ulcers (those identified by the investigators as being at risk for perforation); Active autoimmune diseases (e.g. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, etc.); Severe respiratory diseases (e.g. obstructive pulmonary disease and history of bronchospasm), etc.;

15\. Hemophagocytic cell syndrome;

16\. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) was positive, and the peripheral blood hepatitis B virus (HBV) DNA titer was not within the normal reference range; Hepatitis C virus (HCV) antibody positive and HCV RNA positive in peripheral blood; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA test positive; Who tested positive for syphilis.

Where this trial is running

Zhengzhou, Henan

• Department of Oncology, The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (Recruiting)

Study contacts

• Principal investigator: Zhang Mingzhi Zhang — The First Affiliated Hospital of Zhengzhou University
• Study coordinator: Zhang Mingzhi Zhang, Doctor

Conditions Newly Diagnosed Mantle Cell Lymphoma